Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Tuesday morning,Benzinga reports. They currently have a $18.00 price target on the stock.

Separately, Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Thursday, February 6th.

Coya Therapeutics Price Performance

Coya Therapeutics stock opened at $6.47 on Tuesday. The firm’s 50 day simple moving average is $6.31 and its 200-day simple moving average is $6.48. The company has a market cap of $108.09 million, a P/E ratio of -9.95 and a beta of 0.31. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14. The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Coya Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its stake in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after buying an additional 4,777 shares during the last quarter. XTX Topco Ltd acquired a new position in Coya Therapeutics during the 4th quarter valued at $59,000. Jane Street Group LLC acquired a new position in Coya Therapeutics during the 4th quarter valued at $74,000. Northern Trust Corp raised its stake in Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in Coya Therapeutics during the 4th quarter valued at $401,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.